Sugi Predict

Sugi Predict / Compounds / SCHEMBL5732085

SCHEMBL5732085

SCHEMBL5732085

NS(=O)(=O)c1ccc(-c2cccc(C(Cc3ncco3)C(=O)O)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 15/20 0.43
▸ CA9 Q16790 14/20 0.43
▸ CA12 O43570 10/20 0.43
▸ CA1 P00915 14/20 0.42
▸ CA14 Q9ULX7 3/20 0.41
▸ SYK P43405 1/20 0.39
▸ PPARG P37231 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ CTSS P25774 1/20 0.38
▸ CTSK P43235 1/20 0.38
▸ PTGS2 P35354 1/20 0.37
▸ CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5733048 0.90 CA2 (0.41) CA2CA9CA12CA1CA14
SCHEMBL8153003 0.90 CTSK (0.48) SYKPPARGPPARACTSSCTSK
SCHEMBL5732942 0.89 CA2 (0.43) CA2CA9CA12CA1CA14
SCHEMBL8551224 0.80 CA2 (0.46) CA2CA9CA12CA1CA14
SCHEMBL8146329 0.80 CTSK (0.47) SYKPPARGPPARACTSSCTSK
SCHEMBL5733199 0.78 CA2 (0.41) CA2CA9CA12CA1CA14
SCHEMBL5732592 0.78 LNPEP (0.38) PPARGPPARACTSSCTSK
SCHEMBL5732083 0.69 KMT2A (0.41) CA2CA9CA12CA1CA14
SCHEMBL6215870 0.69 CA2 (0.51) CA2CA9CA12CA1CA14
SCHEMBL5732778 0.68 LNPEP (0.37) CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060251689-A1 Treatment or prevention of pruritus ASTION DEVELOPMENT A/S 2006-11-09 — — US claimed
US-20060229347-A1 Treatment of eczemas ASTION DEVELOPMENT A/S 2006-10-12 — — US claimed
WO-2006102899-A2 OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF ASTION PHARMA A/S (DK) 2006-10-05 — — WO claimed
WO-2006102898-A2 OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA ASTION PHARMA A/S (DK) 2006-10-05 — — WO claimed
WO-2006102900-A1 DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES ASTION PHARMA A/S (DK) 2006-10-05 — — WO claimed
US-20060222671-A1 Dermatological compositions and salts for the treatment of dermatological diseases ASTION DEVELOPMENT A/S 2006-10-05 — — US claimed
EP-1707200-A1 Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases Astion Development A/S (DK) 2006-10-04 — — EP claimed
EP-1707199-A1 Oxaprozin or closely related compound for the treatment and prevention of pruritus Astion Development A/S (DK) 2006-10-04 — — EP claimed
EP-1707201-A1 Oxaprozin or a closely related compound for the treatment of eczema Astion Development A/S (DK) 2006-10-04 — — EP claimed
US-20060251689-A1 Treatment or prevention of pruritus ASTION DEVELOPMENT A/S 2006-11-09 — — US disclosed
US-20060229347-A1 Treatment of eczemas ASTION DEVELOPMENT A/S 2006-10-12 — — US disclosed
WO-2006102898-A2 OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA ASTION PHARMA A/S (DK) 2006-10-05 — — WO disclosed
WO-2006102900-A1 DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES ASTION PHARMA A/S (DK) 2006-10-05 — — WO disclosed
US-20060222671-A1 Dermatological compositions and salts for the treatment of dermatological diseases ASTION DEVELOPMENT A/S 2006-10-05 — — US disclosed
EP-1707200-A1 Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases Astion Development A/S (DK) 2006-10-04 — — EP disclosed
EP-1707201-A1 Oxaprozin or a closely related compound for the treatment of eczema Astion Development A/S (DK) 2006-10-04 — — EP disclosed
EP-1707199-A1 Oxaprozin or closely related compound for the treatment and prevention of pruritus Astion Development A/S (DK) 2006-10-04 — — EP disclosed
US-6090834-A ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS G.D. SEARLE & CO. (US) 2000-07-18 — — US disclosed
EP-0825989-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-03-04 — — EP disclosed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229347-A1 Treatment of eczemas ZAP70, SYK, LCK CA2 1141/4885CA9 3449/4885CA12 2686/4885
US-20060251689-A1 Treatment or prevention of pruritus ITCH, TSLP, HRH4 CA2 329/4885CA9 2296/4885CA12 675/4885
US-20060222671-A1 Dermatological compositions and salts for the treatment of dermatological diseases ZAP70, SYK, LCK CA2 750/4885CA9 3494/4885CA12 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.